Month: March 2026

FREUDENSTADT, Germany, March 06, 2026 (GLOBE NEWSWIRE) — SCHMID Group N.V. (NASDAQ: SHMD) (the “Company”), a global leader in providing solutions to the high-tech electronics, photovoltaics, glass, and energy systems industries, announced today that it has issued the second $15.0 million tranche of its previously announced $30.0 million convertible notes financing under the investment agreement dated January 18, 2026 with an institutional investor (the “Investor“). The Company has issued and sold senior convertible notes in an aggregate principal amount of $30.0 million convertible into ordinary shares of the Company (the “Notes”) together with the issuance of warrants to purchase ordinary shares of the Company (the “Warrants”) in a private placement to the Investor (the Notes and Warrants together, the “Investment...

SINGAPORE, March 06, 2026 (GLOBE NEWSWIRE) — UP Fintech Holding Limited (“UP Fintech” or the “Company”) (NASDAQ: TIGR), a leading online brokerage firm focusing on global investors, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the U.S. market opens on March 19, 2026. UP Fintech’s management will hold an earnings conference call at 8:00 AM on March 19, 2026, U.S. Eastern Time (8:00 PM on March 19, 2026, Singapore/Hong Kong Time). Conference Call Information: All participants wishing to attend the call must preregister online before they may receive the dial-in numbers. Preregistration may require a few minutes to complete. Preregistration Information: Please note that all participants will need to pre-register for the conference call, using the link:  https://register-conf.media-server.com/register/BI64386a93537e41cca665f4023e1048f3 It...

The Extraordinary General Meeting (hereinafter – the Meeting) of shareholders of AB Akola Group (hereinafter – the Company) was held on 6 March 2026. On the Accounting day of the Meeting (27/2/2026) the total number of the Company’s shares is 167,170,481, and the number of shares granting voting rights is 166,605,474. The own shares in the amount of 565,007 acquired by the Company do not grant voting rights. The decisions of the Meeting were adopted on the basis of 14 duly completed general voting ballots submitted prior to the Meeting, representing 134,875,460 share votes, which constitute 80.95 percent of all votes. The quorum existed. Decisions of the Meeting:Election of the assurance service provider for consolidated sustainability report of AB Akola Group.1.1.    Elect UAB ROSK Consulting, code 302692397, as the assurance service...

Press ReleaseVELIZY-VILLACOUBLAY, France — March 6, 2026                 Declaration of the number of outstanding shares and voting rights as of February 28, 2026 Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced below the total number of its outstanding shares and voting rights as of February 28, 2026, according to articles 223-16 and 221-3 of the General Regulation of the Autorité des marchés financiers. Number of outstanding shares: 1,341,855,657 Number of voting rights*: 2,013,481,153 *The total number of voting rights is calculated on the basis of the total number of outstanding shares, even if the voting rights attached thereto are suspended, pursuant to Article 223-11 of the General Regulation of the Autorité des marchés financiers relating to the method for calculating the percentages of holdings in shares...

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global player in pharmaceutical compounding, today publishes its Annual Report 2025, further to its earlier announcement of Fagron’s annual financial results for the financial year 2025 on February 12, 2026. The Annual Report is available on Fagron’s website in both Dutch (official version, including the ESEF-tagged version) and English. It comprises the annual financial report relating to the consolidated financial statements, as well as the sustainability report, for the financial year 2025.  The Annual Report will be presented to the Annual General Meeting of Shareholders, scheduled to be held on May 11, 2026. Financial calendar 9 April 2026                         Trading...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART’s efficacy and safety across subtypes New biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART’s expanding treatment approach in CIDPMarch 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) and pipeline candidates empasiprubart and adimanebart at the 2026 American Academy...

(Oslo, 6 March 2026) Hexagon Purus, a world leading manufacturer of zero emission mobility and infrastructure solutions, has received purchase orders for the delivery of hydrogen distribution units from a leading Central European integrated energy company. The total value of the order is approximately EUR 6.2 million and is scheduled for delivery in Q3 and Q4 2026. “We are happy to welcome this new customer and to provide distribution units that will transport hydrogen to this leading European energy company’s growing mobility infrastructure network”, says Morten Holum, CEO of Hexagon Purus. “This order is a direct result of our recent efforts to diversify the customer base and contributes to strengthening our order book for the second half of 2026”. For more information: Mathias Meidell, Investor Relations Director, Hexagon PurusTelephone:...